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Background: Standard cytogenetic analysis has revealed to date more than 30 reported cases presenting interstitial
deletions involving region 2q31-q32, but with poorly defined breakpoints. After the postulation of 2q31.2q32.3
deletion as a clinically recognizable disorder, more patients were reported with a critical region proposed and
candidate genes pointed out.
Results: We report two female patients with de novo chromosome 2 cytogenetically visible deletions, one of them
with an additional de novo deletion in chromosome 20p12.2p12.3. Patient I presents a 16.8 Mb deletion in
2q31.2q32.3 while patient II presents a smaller deletion of 7 Mb in 2q32.1q32.3, entirely contained within patient I
deleted region, and a second 4 Mb deletion in Alagille syndrome region. Patient I clearly manifests symptoms
associated with the 2q31.2q32.3 deletion syndrome, like the muscular phenotype and behavioral problems, while
patient II phenotype is compatible with the 20p12 deletion since she manifests problems at the cardiac level,
without significant dysmorphisms and an apparently normal psychomotor development.
Conclusions: Whereas Alagille syndrome is a well characterized condition mainly caused by haploinsufficiency of
JAG1 gene, with manifestations that can range from slight clinical findings to major symptoms in different domains,
the 2q31.2q32.3 deletion syndrome is still being delineated. The occurrence of both imbalances in reported patient
II would be expected to cause a more severe phenotype compared to the individual phenotype associated with
each imbalance, which is not the case, since there are no manifestations due to the 2q32 deletion. This, together
with the fact that patient I deleted region overlaps previously reported cases and patient II deletion is outside this
common region, reinforces the existence of a critical region in 2q31.3q32.1, between 181 to 185 Mb, responsible for
the clinical phenotype.
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Standard cytogenetic analysis has revealed to date more
than 30 reported cases presenting interstitial deletions in-
volving region 2q31-q32, but with poorly defined break-
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two additional patients, with the last one refining a critical
region for the syndrome and pointing out candidate genes
to explain the phenotype. The common clinical features
include pre- and postnatal growth retardation, severe
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hernia and broad-based gait [1].
An already established condition is Alagille syndrome
(AGS - OMIM 118450), a multi-system, dominantly
inherited developmental disorder [6]. AGS maps to
20p12 and is mainly caused by haploinsufficiency of the
Jagged-1 gene (JAG1- OMIM 601920), due to mutations
in 70% of the cases and to deletions in 3-7% of the
patients [6]. The clinical manifestations of the syndrome
are highly variable, ranging from slight clinical findings
to major symptoms in 5 domains: cardiac, skeletal, ocu-
lar, facial and liver [6].
We report two different female patients with chromo-
some 2 deletions, both de novo. Patient I presents a
16.8 Mb deletion in 2q31.2q32.3 while patient II
presents a smaller deletion of 7 Mb in 2q32.1q32.3,
entirely contained within patient I deleted region.
Besides this deletion patient II also presents a de novo
4 Mb deletion in 20p12.2p12.3 Alagille syndrome region.
Patient I manifests symptoms clearly associated with the
2q31.2q32.3 deletion syndrome, while patient II manifes-
tations are exclusively associated with AGS. As the
region deleted exclusively in patient I, and normal in
patient II, overlaps the previously reported deletions [3-5],
we intent to contribute to the refinement of the critical




Girl with 8 years and 9 months old, the second female child
of healthy unrelated parents with an unremarkable family
history. The pregnancy was uneventful, without any signs
of intrauterine growth restriction and the birth was normal
at 36 weeks gestation. Birth weight was 2470 g (50th cen-
tile), birth length 44 cm (10th centile) and birth head cir-
cumference 32.5 cm (50th centile). At the age of 8 years
her height was 124.5 cm (25th centile), her weight 25.3 kg
(50th centile) and head circumference 52.5 cm (75th centile).
In the first year of life she had recurrent episodes of dacryo-
cystitis and feeding problems, but nowadays she has uncon-
trollable eating habits which her parents cope with
successfully. She has behavioral problems, with some ag-
gressively and an unpredictable humor, but has an active
speech. According to the Wechsler Intelligence Scale for
Children (WISC), she has mild mental retardation with a
full scale IQ score of 69, verbal IQ score of 73 and perform-
ance IQ score of 75. Distinguishing features include thick
and coarse hair, dry skin, brachycephaly with a large but
narrow forehead, deep set eyes and midface hypoplasia.
The palate is high and narrow, similarly to her mother and
other familiars. She has bilateral tapering fingers, sandal
gap and limb muscle hypertrophy with difficulties in motor
coordination and fine motor skills.Patient II
Three year-old girl, the third child of a healthy unrelated
couple, with an unremarkable family history. She was
born at 36 weeks of gestation, but at 34 weeks was identi-
fied an oligohydramnios. Cytogenetic prenatal diagnosis
due to advanced maternal age was performed in another
laboratory and revealed a normal karyotype. At delivery
her birth weight was 2164 g (between the 25th and the
75th percentile), birth length 43 cm (3rd percentile) and
birth occipitofrontal circumference (OFC) 30 cm (below
the 5th percentile). Her Apgar score (9 at the first minute
and 10 at the fifth minute) was normal. In the neonatal
period she was admitted in a neonatal intensive care unit
for 20 days due to a urinary tract infection. Complemen-
tary diagnostic exams revealed a congenital heart disease
characterized by a subaortic ventricular septal defect, pul-
monary stenosis and a patent ductus arteriousus. The renal
ultrasound made the diagnosis of a vesicoureteral reflux.
Clinical examination at 19 months revealed no significant
dysmorphisms with an apparently normal psychomotor
development. Her standing height (77.5 cm, 10th percent-
ile) and OFC (46 cm, 25th percentile) were normal, but her
weight was below the 5th percentile (9.040 g).
Standard cytogenetic analysis of peripheral blood lym-
phocytes was performed on both patients revealing
imbalances on chromosome 2 that were further charac-
terized by oligoarray-CGH.
Results
Chromosomal analysis of G-banded metaphases from pro-
bands and their progenitors showed both patients to have
de novo (paternity and maternity confirmed) interstitial
deletions in chromosome 2 between bands 2q32.1q32.3
(Figure 1A-C). Karyotypes of both girls were
46,XX,del(2)(q32.1~q32.3)dn.
Oligoarray-CGH analysis confirmed both deletions
spanning in patient I about 16.8 Mb of genomic DNA
and in patient II 7 Mb (Figure 2A-C). In patient I the
deletion involves 72 genes from position 178,121,127 bp
(clone A_16_P00537150) to 194,943,948 bp (clo-
ne_A16_P36015481), with the proximal breakpoint be-
tween 178,112,041 bp and 178,112,127 bp and the distal
breakpoint between 194,943,948 bp and 194,976,996 bp
(mapped according to GRCh37, hg 19) (Figure 2B, D).
Patient I final karyotype was:
46,XX,del(2)(q32.1 ~ q32.3).arr 2q31.2q32.3(178,121,127-
194,943,948)x1 dn.
In patient II the deletion involves 37 genes from position
186,138,564 bp (clone A_16_P15961767) to 193,143,843 bp
(clone A_18_P13572014) with the proximal breakpoint
Figure 1 Conventional cytogenetic results: Ideogram of chromosome 2 locating the deletion (A), conventional GTG banded pair of
chromosomes 2 from patients I (B) and II with the deleted chromosome on the right (C), ideogram of chromosome 20 locating the deletion (D)
and pair of chromosomes 20 from patient II (E).
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breakpoint between 193,143,843 bp and 193,194,619 bp
(mapped according to GRCh37, hg 19) (Figure 2C, E). Oli-
goarray-CGH analysis also disclosed an unexpected
20p12.2p12.3 deletion in patient II spanning about 4 Mb
and involving 13 genes from position 7,993,915 bp (clone
A_16_P21064860) to position 11,937,684 bp (clone
A_16_P03485400). The distal breakpoint is between
7,982,406 bp and 7,993,915 bp and the proximal breakpoint
between 11,937,684 bp and 11,982,565 bp (mapped accord-
ing to GRCh37, hg 19) (Figure 2F-H). Revisiting standard
G-banded metaphases it is not possible to detect the
20p12.2p12.3 deletion with certainty, since it is within a
cytogenetic difficult region (Figure 1D-E). MLPA SALSA
P297-B1 for microdeletion syndromes (MRC-Holland) con-
tains two probes for gene PAK7, included in the 20p dele-
tion. It allowed us to confirm the proband’s deletion and to
conclude it is de novo (paternity and maternity confirmed).




Conventional cytogenetic evaluation of the reported
patients revealed chromosome 2q32 deletions that
were confirmed and refined by oligoarray-CGH. This
molecular technique also revealed a 20p12 deletion in
the Alagille syndrome region in patient II, enabling us
to conclude that one of the reported patients presents
two de novo deletions in two different chromosomes,
both associated with described syndromes.
In patient I, chromosome 2 deleted region involves 72
genes, with 14 reported in OMIM Morbid Map, and in
patient II it involves 37 genes, all in common with pa-
tient I. Of the 37 genes that are deleted in both patients,6 are described in the OMIM Morbid Map (Figure 3).
One of those genes is MSTN (myostatin - OMIM
601788) whose loss-of-function mutations are associated
with muscle hypertrophy, the increase of the size of
muscle cells [7]. While reported patient I presents a
muscular phenotype and an inadequate strength to her
age, patient II does not present such features. We cannot
disregard the reduced age of patient II, that might justify
the actual absence of manifestations related to MSTN dele-
tion, but this is also in accordance with Prontera et al. [4]
argument that the manifestation of a muscular phenotype
can occur in patients with larger 2q31.2q32.3 deletions ra-
ther than in those with more distal deletions.
Considered as a possible candidate gene for the behav-
ioral phenotype in patients with 2q32 deletions is GLS
(glutaminase, phosphate-activated - OMIM 138280),
that encodes the major enzyme yielding glutamate
from glutamine, whose importance is derived from its
probable implication in behavior disturbances in which
glutamate acts as a neurotransmitter [8,9]. This gene is
deleted in both patients, and while patient I presents
behavioral problems, patient II has an apparently nor-
mal psychomotor development to date. Meanwhile,
according to the haploinsufficiency scores defined by
the study of Huang et al. [10], GLS has a score of
69%, making it a gene more likely to be haplosuffi-
cient. Considering this data and the absence of mani-
festations in reported patient II, the behavioral
phenotype in patient I might be caused by the deletion
of ZNF804A gene (zinc finger protein 804A - OMIM
612282), whose haploinsufficiency score is 32%. This
score together with the described involvement of zinc
finger genes in mental retardation make ZNF804A a
candidate gene for cognitive and behavioral distur-
bances, consistently with previous findings involving
other zinc-finger genes in mental retardation [11-16].
Figure 2 Oligoarray-CGH ratio profiles for chromosomes 2 and 20: chromosome 2 ideogram (A), Log2 ratio of chromosome 2 probes
plotted as a function of chromosomal position for patients I (B) and II (C), genes involved in the 2q32deletion of patients I (D) and II (E);
chromosome 20 ideogram (F), Log2 ratio of chromosome 20 probes plotted as a function of chromosomal position for patient II (G), genes
involved in the 20p12 deletion of patient II (H). Each spot represents a probe, with the patient DNA labeled in red (Cy5) and the control DNA
labeled in green (Cy3). Log2 ratios of zero represent equal fluorescence between both samples and the log2 ratio of -1 means copy number loss
of the sample DNA.
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II, 8 other genes are described in OMIM Morbid Map,
being the most relevant probably FRZB (frizzled-related
protein - OMIM 605083) and CERKL (ceramide kinase-like
- OMIM 608381) (Figure 3). FRZB gene codes for a protein
that might play a role in skeletal morphogenesis [17] and
thus can be a candidate gene for the craniofacial and hand/
foot abnormalities described in patients with this deletion,
since they commonly present tapering fingers at the hands
and sandal gap at the feet [3-5] as in reported patient I.
Haploinsufficiency of CERKL in patient I might justify her
cognitive impairment when compared to patient II, since it
codes for ceramide kinases that convert ceramide into cer-
amide-1-phosphate, both key mediators of cellular apop-
tosis and survival [18]. One gene also deleted only in
patient I, ITG4A (integrin alpha-4 - OMIM 192975), has
been reported to be associated with autism in two different
studies [19,20]. Cocchella et al. [5] postulated it to be a
candidate gene for the behavioral manifestations and for
the speech disorders observed in patients with 2q31.2q32.3deletion, and the patient reported by Manolakos et al. [21],
whose deletion includes ITG4A, also presents a speech lim-
ited to simple vocalization with lack of meaning. However,
although our reported patient I presents behavioral pro-
blems she has an active speech, so we consider that ab-
sence of speech should be excluded of the core phenotype
of 2q31.2q32.3 deletion as proposed by Cocchella et al. [5].
Concerning patient II, the cryptic imbalance detected
by oligoarray-CGH at 20p12 is compatible with her clin-
ical manifestations. Of the 13 genes deleted, 3 are
described in OMIM Morbid Map, MKKS (McKusick-
Kaufman syndrome - OMIM 604896), PLCB1 (phospho-
lipase C, beta 1 - OMIM 607120) and JAG1 genes.
MKKS and PLCB1genes are associated with McKusick-
Kaufman syndrome (OMIM 236700) and Early Infantile
Epileptic Encephalopathy-12 (OMIM 613722), respect-
ively, both autosomal recessive disorders.
As already mentioned, JAG1 gene haploinsufficiency is
responsible for Alagille syndrome, whose clinical manifes-
tations are highly variable [6]. Of the five clinical criteria
Figure 3 Patients I and II chromosome 2 deletion compared to four previously reported patients. OMIM Morbid Map genes are in red
and other genes discussed in the text are in green. The dotted black rectangle delimitates the common deleted region among the patients.
Breakpoints mapped according to GRCh37, hg 19.
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tations at the cardiac level. This case might be one of those
cases with low penetrance and expressivity [22] or the ab-
sence of additional clinical manifestations might be due to
the reduced age of the proband. A challenge is put upon
the clinical geneticist to do the follow-up of the child de-
velopment, in order to establish a definitive phenotype and
a correlation with the two reported chromosomal imbal-
ances. The occurrence of both abnormalities would be
expected to cause a more severe phenotype compared to
the individual phenotype associated with each imbalance,
which is not the case. We cannot rule incomplete pene-
trance of this imbalance. Taking into consideration that
reported patient II does not present clinical features usually
reported in 2q31.2q32.3 deletion syndrome, we can suggest
that the critical region associated with the phenotype is
outside patient II deleted region. As patient I manifests
phenotypic features common to the other reported
patients in the literature and their deletions overlap a com-
mon region, our results support Cocchella et al. [5] sugges-
tion that the main phenotype is probably caused by the
involvement of a small segment between 2q31.2q32.3. Fur-
thermore we suggest that the critical region should involve
bands 2q31.3q32.1 between 181 to 185 Mb, containing
CERKL, FRZB, ZNF804A and ITG4A genes discussedabove (Figure 3). We did not consider the distal breakpoint
of the patient reported by Manolakos et al. [21] since her
phenotype is restricted to mental retardation and limited
speech, probably related to the involvement of genes like
CERKL and ITG4A. FRZB gene is normal in this patient,
which is consistent with the absence of craniofacial and
hand/foot abnormalities features that are common to
patients with deletions involving this gene.
Establishing a syndrome with defined clinical characteris-
tics is still difficult, due to the reported diversity of manifes-
tations and phenotypes severity. Report of more cases fully
characterized at a clinical and molecular level will be of
major importance to definitely define the critical region of
2q31.2q32.3 deletion syndrome and to establish the core
phenotype.
Patient II illustrates that multiple chromosome abnormal-
ities in the same patient might be, to date, underestimated,
because without oligoarray-CGH analysis and typical clin-
ical manifestations of Alagille syndrome, the 20p12 deletion
would not be identified and the proband’s phenotype would
only be attributed to the 2q32 deletion. Array-CGH is a
valuable and cost effective tool to detect cryptic genomic
imbalances, to further characterize cytogenetically detected
alterations and to accurately estimate the frequency of
patients with multiple chromosome imbalances.
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Conventional cytogenetic analysis
Conventional GTG banding, done according to standard
protocols, was performed on peripheral blood lymphocytes
of both probands and their progenitors [23]. Karyotypes
were established according to the International System for
Human Cytogenetic Nomenclature (ISCN) 2009 [24].
Array-CGH
Precise determination of the breakpoints in the probands
chromosomal imbalances was performed using Agilent
SurePrint G3 Human Genome microarray 180 K (Agilent
Technologies, Santa Clara, CA, USA), an oligonucleotide
microarray containing approximately 180 000 60-mer
probes with a 17 Kb average probe spacing. Genomic
DNA of both patients was extracted from peripheral blood
lymphocytes using Jetquick blood and cell culture DNA
Midi Spin kit (Genomed, Löhne, Germany). Genomic DNA
of a normal female control was obtained from Promega
(Madison, WI, USA). Labeling was performed using Agilent
Genomic DNA enzymatic labeling kit (Agilent) according
to the manufacturers’ instructions. After hybridization, the
oligoarray-CGH slide was scanned on an Agilent scanner,
processed with Feature Extraction software (v10.7) and
results were analyzed using Agilent Genomic Workbench
(v6.0) with the following settings: ADM2 as aberration algo-
rithm, threshold of 6.0, moving average 2 Mb.
MLPA was used to confirm oligoarray-CGH result for
chromosome 20 [25] in patient II with commercially
available SALSA P297-B1 for Microdeletion syndromes
(MRC-Holland, Amsterdam, Netherlands) and was per-
formed according to the manufacturers’ instructions.
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